What if aging is not inevitable, but a solvable biological problem?

In this episode of The CTO Show with Mehmet, Mehmet sits down with Dr. Bill Andrews, a renowned molecular geneticist and pioneer in telomere research. Dr. Andrews has spent decades studying the mechanisms of aging and is known for leading discoveries around telomerase, the enzyme connected to cellular aging.

The conversation explores the biological root causes of aging, the role of telomeres in limiting human lifespan, and the scientific pursuit of extending human healthspan. Dr. Andrews also shares insights into the challenges of biotech innovation, the economics of pharmaceutical research, and why breakthroughs in longevity science often struggle to reach the public.

This episode bridges biology, technology, and the future of human health, offering a deep dive into one of the most fascinating scientific frontiers of our time.

⸻

About the Guest

Dr. Bill Andrews is a molecular biologist and geneticist recognized for his groundbreaking work in telomere and telomerase research. Over his career, he has contributed to the discovery and development of multiple biotechnology innovations, including therapies related to cancer and genetic diseases.

Dr. Andrews holds more than 50 patents in genetics and biotechnology and has dedicated his career to understanding the biological mechanisms of aging and developing solutions to extend healthy human lifespan.

He is the founder of Sierra Sciences, a biotechnology company focused on discovering ways to activate telomerase and address the root causes of aging.

https://www.linkedin.com/in/william-h-andrews-ceo-5455b45/

⸻

Key Takeaways

• Aging may be driven by the shortening of telomeres, protective caps at the ends of chromosomes.

• The Hayflick Limit suggests human cells can only divide a finite number of times.

• Telomerase is an enzyme that can extend telomeres, potentially slowing or reversing aspects of aging.

• Longevity research faces major challenges due to funding structures and biotech investment models.

• Many scientists believe extending healthspan, not just lifespan, should be the primary goal of longevity science.

• Advances in biotechnology could eventually transform aging from an inevitability into a treatable biological process.

⸻

What You Will Learn

• Why aging occurs from an evolutionary and genetic perspective

• How telomeres influence cellular aging and lifespan

• The role of telomerase in longevity research

• Why curing aging is scientifically complex and financially challenging

• The relationship between aging and diseases such as cancer and Alzheimer’s

• How biotech innovation may shape the future of human longevity

⸻

Episode Highlights

00:00 Introduction to Dr. Bill Andrews and longevity research

02:00 Why humans age from an evolutionary perspective

06:30 Healthspan vs lifespan and the goals of longevity science

10:00 The Hayflick Limit and the biological clock of cells

13:30 Discovering telomeres and telomerase

18:00 The search for molecules that activate telomerase

22:00 How scientists measure aging and longevity

27:00 Why curing aging is scientifically and financially difficult

34:00 The role of pharmaceutical companies and research incentives

41:00 The economics of biotech innovation

48:00 Longevity research in animals and pets

55:00 The broader vision for curing aging

⸻

Resources Mentioned

• Sierra Sciences: https://sierrasci.com/

• Up One Podcast: https://podcasts.apple.com/us/podcast/up-one/id1815282315?ls=1

In this episode of The CTO Show with Mehmet, Mehmet Gonullu sits down with Betsy Atkins, serial entrepreneur, board member of global companies, and advisor to leading organizations including Google Cloud.

The conversation explores how the role of the board is evolving in an era defined by AI, agentic systems, and accelerating technological change. Betsy shares deep insights on how boards must move from passive oversight to active orchestration, the risks introduced by agentic AI, and what leaders must do today to stay relevant.

From “corporate cholesterol” slowing down organizations to the emergence of AI governance frameworks, this episode offers a candid look at the challenges and opportunities shaping the next generation of leadership.

⸻

👤 About the Guest

Betsy Atkins is a three-time CEO, serial entrepreneur, and globally recognized corporate governance expert. She has served on over 30 public and private company boards and currently sits on the Google Cloud Advisory Board, as well as boards including Wynn Resorts and goPuff.

Betsy brings decades of experience across venture capital, private equity, and public markets, advising leadership teams on digital transformation, governance, and innovation.

⸻

🔑 Key Takeaways

• Boards are shifting from passive oversight to active involvement in technology and innovation

• Agentic AI introduces new risks that require structured governance and monitoring

• “Corporate cholesterol” slows companies down as they scale and must be actively removed

• AI governance will become as critical as cybersecurity oversight

• Founder-led companies must carefully select board members based on mindset, not just resumes

• Decision speed and adaptability are now core competitive advantages

• There is currently no clear “kill switch” for agentic AI systems, creating new risk categories

• Investors must rethink due diligence to properly evaluate AI-driven companies

⸻

📚 What You Will Learn

• How the role of the board is evolving in the age of AI

• The concept of “corporate cholesterol” and how it impacts growth

• How to build AI governance frameworks inside organizations

• The real risks behind agentic AI and autonomous systems

• What founders should look for when building their boards

• How investors should evaluate AI capabilities during due diligence

• Why execution speed is becoming a key differentiator

• The future of leadership in an AI-driven world

⸻

⏱️ Episode Highlights

00:00 Introduction and Betsy Atkins’ background

02:45 How boards have evolved from oversight to active engagement

05:30 The concept of “corporate cholesterol” and organizational drag

08:40 Innovation vs. risk in public and private companies

11:00 Founder-led boards and selecting the right directors

17:30 AI’s impact on organizational structure and decision-making

21:00 Agentic AI risks and real-world experiments

25:00 Balancing innovation and governance in AI adoption

30:00 Who owns AI governance inside the organization

33:00 The need for monitoring, orchestration, and control systems

35:30 The “kill switch” debate and future AI risk

40:30 AI due diligence for investors and common mistakes

44:30 Key technology trends shaping the next decade

48:00 Optimism vs. risk in the future of AI

⸻

🔗 Resources Mentioned

• Betsy Atkins Website: https://betsyatkins.com/

• Betsy Atkins LinkedIn: https://www.linkedin.com/in/betsy-atkins-a36b114/

• Anthropic research on AI agent behavior: https://www.anthropic.com/research/agentic-misalignment

Tokenization has moved beyond hype. The real opportunity is no longer in creating tokens, but in building the infrastructure that allows real-world assets to operate at scale.

In this episode, Mehmet speaks with GP Worrell, Co-Founder and CPO of Blubird, about the evolution of Web3 from speculation to systems. They explore why most tokenization projects fail, how modular infrastructure changes time-to-market, and why compliance, trust, and operational systems are becoming the true moats in the space.

The conversation also dives into AI’s role in Web3, the shift from ICO-era hype to real assets, and what it takes to build scalable, institutional-grade platforms in a rapidly maturing market.

⸻

👤 About the Guest

GP Worrell is the Co-Founder and Chief Product Officer at Blubird, a platform focused on building the infrastructure layer for tokenized real-world assets.

With over two decades of experience across enterprise systems, fintech, and blockchain, GP has been active in the Web3 space since 2016. At Blubird, he focuses on enabling institutional-grade tokenization through compliance, governance, onboarding, reporting, and lifecycle management.

⸻

🚀 Key Takeaways

• Tokenization alone is not enough, infrastructure is where long-term value is created

• Most projects fail not because of tech, but due to lack of market fit and distribution

• Modular platforms dramatically reduce time-to-market from months to weeks

• Compliance, governance, and reporting are critical for institutional adoption

• Real-world assets differ fundamentally from NFTs and speculative tokens

• Infrastructure creates operational trust across issuers, investors, and regulators

• AI will play a supporting role, especially in compliance and decision-making workflows

• The Web3 market is maturing, but still far from fully developed

⸻

🎯 What You’ll Learn

• Why tokenization is shifting from hype to infrastructure

• How modular systems are transforming Web3 development

• The biggest mistakes founders make in the RWA space

• What makes a tokenization platform scalable and compliant

• How regulators view trust in tokenized assets

• The role of AI in Web3 platforms and infrastructure

• The future of tokenization in real estate, commodities, and beyond

⸻

⏱️ Episode Highlights

00:00 – Introduction and GP’s background

01:00 – What Blubird is building in tokenization infrastructure

02:00 – Why infrastructure matters more than tokens

03:00 – From bespoke tokenization to modular systems

04:00 – Common mistakes founders make in Web3

05:00 – Explaining tokenization using Web2 analogies

06:00 – Real-world asset examples and use cases

07:00 – What is defensible in tokenization platforms

08:00 – Speed, scale, and time-to-market advantages

09:00 – Compliance, KYC, AML and institutional requirements

10:00 – Trust, regulators, and infrastructure layers

11:00 – Impact on investor confidence and adoption

12:00 – Government use cases and institutional focus

13:00 – Tokenization as a fundraising tool for founders

14:00 – Why infrastructure alone is not enough

16:00 – Market fit, GTM, and why projects fail

18:00 – Blockchain choice vs business fundamentals

19:00 – The role of AI in tokenization platforms

21:00 – Product leadership in Web3 vs Web2

24:00 – Emerging use cases beyond real estate

26:00 – Lessons from ICOs and market evolution

29:00 – Why the market is maturing but not mature

31:00 – Parallels between Web1, AI, and Web3

34:00 – The future “ChatGPT moment” for tokenization

35:00 – Final thoughts and where to connect

⸻

🔗 Resources Mentioned

• Blubird: https://www.getblubird.com/

• GP Worrell on LinkedIn: https://www.linkedin.com/in/gpworrell/